Network meta-analysis of 33 RCTs (5045 hospitalised patients): melatonin/melatonin receptor agonists (RR 0.77) and suvorexant (RR 0.51) were associated with lower delirium risk vs non-active control; midazolam showed no significant reduction (RR 1.64). Low–moderate certainty.
Meta-analysisn = 5,045
Chen et al. Sleep-modulating pharmacological interventions for delirium prevention: a systematic review and a network meta-analysis of randomized controlled trials